netFormulary Oxfordshire Clinical Commissioning Group NHS
Formulary  
 Search
 Formulary Chapter 3: Respiratory system - Full Chapter
Chapter Links...
 Details...
03.01.01.01  Expand sub section  Selective Beta2 agonists
03.01.01.01  Expand sub section  Short-acting beta2 agonists
03.01.01.01  Expand sub section  Long-acting beta2 agonists
Formoterol fumarate (Oxis® Turbohaler)
View adult BNF View SPC online View childrens BNF
Formulary
Green

For COPD patients use Oxis® 12 Turbohaler in line with Guidance on COPD Management in Primary care - Inhaled Therapies.

APCO March 2017.

 
   
Olodaterol (Striverdi Respimat®)
View adult BNF View SPC online View childrens BNF
Formulary
Green

In line with Guidance on COPD Management in Primary care - Inhaled Therapies.

APCO March 2017.

 
   
Formoterol Fumarate (Atimos® Modulite)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Brown

Atimos® should not be initiated for new patients for COPD or asthma.

People whose treatment with Atimos® is not recommended in the Guidance on COPD Management in Primary care—Inhaled Therapies or Maintenance Management of Asthma – Inhaled and Oral Therapies (adults) but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

NB. For asthma use ICS/LABA combination inhaler as per guidance.

 
   
Formoterol fumarate (Easyhaler 12micrograms/dose)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Brown

Formoterol Easyhaler® should not be initiated for new patients for COPD or asthma.

People whose treatment with Formoterol easyhaler® is not recommended in the Guidance on COPD Management in Primary care—Inhaled Therapies or Maintenance Management of Asthma – Inhaled and Oral Therapies (adults) but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

NB. For asthma use ICS/LABA combination inhaler as per guidance.

 
   
Salmeterol
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
Brown

Salmeterol 25mcg should not be initiated for new patients for COPD or asthma.

People whose treatment with Salmeterol 25mcg is not recommended in the Guidance on COPD Management in Primary care—Inhaled Therapies or Maintenance Management of Asthma – Inhaled and Oral Therapies (adults) but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

NB. For asthma use ICS/LABA combination inhaler as per guidance.

 
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Red: Medicines which should only be prescribed in secondary care by a specialist.  

Amber Continuation

Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.   

Amber Shared Care Protocol

Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).   

Green

Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.   

Brown

Brown: Medicines which should only be prescribed in restricted circumstances.  

Black

Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.  

OCCG Green

not used  

netFormulary